Physician profile
Robert N Gerstman
NPI 1689680795
$5,921.12
in general payments reported to CMS, 2019-2025
12 companies · $1,231 in 2025
The $1,231 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $188 · 2021: $601 · 2022: $685 · 2023: $1,215 · 2024: $1,510 · 2025: $1,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,845 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,845.06 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,439.02 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $1,064.84 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $857.63 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $590.02 | 2020-2024 | Caplyta |
| Abbvie INC. | $526.23 | 2021-2025 | |
| Axsome Therapeutics, INC. | $374.99 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $365.09 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $327.48 | 2024-2025 | Cobenfy |
| Indivior INC. | $129.33 | 2022-2023 | Perseris |
| Bioxcel Therapeutics, INC. | $125.00 | 2023 | Igalmi |
| Sage Therapeutics, LLC | $89.86 | 2020 | |
| Janssen Pharmaceuticals, INC | $31.63 | 2025 | Invega Sustenna, Invega Trinza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gerstman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.